- Hemogenyx Pharmaceuticals Plc’s (HEMO) wholly owned subsidiary, Immugenyx, LLC has entered into a research agreement with a global pharmaceutical company.
- The global company who has requested to keep its identity confidential will pay USD75,000 to Immugenyx for the research done by it.
- The global company will be getting a worldwide, non-exclusive, royalty-free licence from Immugenyx to any know-how and any patent(s) and patent application(s) coming from the agreement to be used for their own purposes.
- On 23rd October 2019, at the time of writing, GMT 08:02 AM, HEMO shares were trading at GBX 2.15, up by 0.10 points or 4.88% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.